Research Publications 2018-10-11T03:01:40+00:00

Our research is published in leading national and international journals to share the results of our studies with peers around the world.

Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A. Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study. BMC Med Ethics. 2016 Oct 21;17(1):63. PubMed PMID: 27769273. https://doi.org/10.1186/s12910-016-0144-y

Jameson MG, McNamara J, Bailey M, Metcalfe PE, Holloway LC, Foo K, Do V, Mileshkin L, Creutzberg CL, Khaw P. Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial. J Med Imaging Radiat Oncol. 2016 Aug; 60(4):554-9. https://doi.org/10.1111/1754-9485.12447 Epub 2016 Apr 5.

de Boer, S.M., M.E. Powell, L. Mileshkin, D. Katsaros, P. Bessette, C. Haie-Meder, P.B. Ottevanger, J.A. Ledermann, P. Khaw, A. Colombo, A. Fyles, M.H. Baron, H.C. Kitchener, H.W. Nijman, R.F. Kruitwagen, R.A. Nout, K.W. Verhoeven-Adema, V.T. Smit, H. Putter, C.L. Creutzberg, and P.s. group, Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol, 2016. 17(8): https://www.ncbi.nlm.nih.gov/pubmed/27397040

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993. https://doi.org/10.1002/cncr.30414 Epub 2016 Nov 16.

K. Wilson, E. Pujade-Lauraine, D. Aoki, M. R. Mirza, D. Lorusso, A. M. Oza, A. du Bois, I. Vergote, A. Reuss, M. Bacon, M. Friedlander, D. Gallardo-Rincon, F. Joly, S.-J. Chang, A. M. Ferrero, R. J. Edmondson, P. Wimberger, J. Maenpaa, D. Gaffney, R. Zang, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the Fifth Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Ann Oncol 2016 mdw663. https://doi.org/10.1093/annonc/mdw663

McGee, M. Bookman, P. Harter, C. Marth, I. McNeish, K. N. Moore, A. Poveda, F. Hilpert, K. Hasegawa, M. Bacon, C. Gatsonis, A. Brand, F. Kridelka, J. Berek, N. Ottevanger, T. Levy, S. Silverberg, B.-G. Kim, H. Hirte, A. Okamoto, G. Stuart, K. Ochiai, and on behalf of the participants of the 5th Ovarian Cancer Consensus Conference; Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol 2017 mdx010. https://doi.org/10.1093/annonc/mdx010

Mercieca-Bebber, R., Friedlander, M., Calvert, M. et al. J A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice (2017) 1: 5. https://doi.org/10.1186/s41687-017-0008-3

Yoland Catherine Antill, Martin R. Stockler, Peey Sei Kok, Kristy Pamela Robledo, Kim Gillies, John Stark, Sonia Yip, Linda R. Mileshkin, and Australia New Zealand Gynaecological Oncology Group (ANZGOG). A phase II trial of durvalumab (Medi 4736) in advanced endometrial cancer: PHAEDRA. Journal of Clinical Oncology 2017 http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS5614

Cohen PA, Brand A, Sykes P, et al. Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. BMJ Open 2017;7:e017576. https://doi.org/10.1136/bmjopen-2017-017576

Lindemann K, Kok PS, Stockler M, Sykes P, Brand A. Enhanced recovery after surgery for suspected ovarian malignancy: A survey of perioperative practice amongst gynecogical oncologists in Australia and New Zealand to inform a clinical trial. Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: https://doi.org/10.1097/IGC.0000000000000982

Florence Joly, Felix Hilpert, Aikou Okamoto, Gavin Stuart, Kasunori Ochiai, Michael Friedlander, Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer, European Journal of Cancer, Volume 78, June 2017, Pages 133-138, ISSN 0959-8049, https://doi.org/10.1016/j.ejca.2017.03.019

Bonaventura A1, OʼConnell RL, Mapagu C, Beale PJ, McNally OM, Mileshkin LR, Grant PT, Hadley AM, Goh JCH, Sjoquist KM, Martyn J, DeFazio A, Scurry J, Friedlander ML; Paragon Investigators. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. Int J Gynecol Cancer. Jun 2017; 27(5):900–906, https://doi.org/10.1097/IGC.0000000000000978

Roncolato FT, Joly F, O’Connell R, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Pignata S, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Heitz F, Feeney A, Berton-Rigaud D, Stockler MR, King M, Friedlander M; GCIG Symptom Benefit group. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.Oncologist. 2017 Jun 8. pii: theoncologist.2017-0047. https://doi.org/10.1634/theoncologist.2017-0047  [Epub ahead of print] PMID: 28596446

Mercieca-Bebber, R., Friedlander, M., Kok, PS. et al. The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols. (2016) 25: 2457. https://doi.org/10.1007/s11136-016-1339-x

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery programs for ovarian cancer – a systematic review to identify candidate interventions. Int J Gynecol Cancer. 2017 May 12. https://doi.org/10.1097/IGC.0000000000000981

Lindemann K, Kok PS, Stockler M, Jaaback K, Brand A. Enhanced recovery after surgery for advanced ovarian cancer: A systematic review of interventions trialed. Int J Gynecol Cancer. 2017 Jul;27(6):1274-1282. https://doi.org/10.1097/IGC.0000000000000981Review. PubMed PMID: 28498237.

Clamp, A.R., I. McNeish, A. Dean, D. Gallardo, J. Weon-Kim, D. O’Donnell, J. Hook, C. Coyle, S.P. Blagden, J. Brenton, R. Naik, T. Perren, S. Sundar, A. Cook, E. James, A.M. Swart, S. Stenning, R. Kaplan, and J. Ledermann, 929O_PRICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology, 2017. 28(suppl_5): https://oncologypro.esmo.org/Meeting-Resources/ESMO-2017-Congress/BRIM8-a-randomized-double-blind-placebo-controlled-study-of-adjuvant-vemurafenib-in-patients-pts-with-completely-resected-BRAFV600-melanoma-at-high-risk-for-recurrence

Friedlander, M., R.L. Mercieca-Bebber, and M.T. King, Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned. Ann Oncol, 2016. 27 Suppl 1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5934909/

Lim, K., van Dyk, S., Khaw, P., Veera, J., Mileshkin, L., Ohanessian, L., Harrison, M. and Vinod, S. K. (2017), Patterns of practice survey for brachytherapy for cervix cancer in Australia and New Zealand. J Med Imaging Radiat Oncol.  https://www.ncbi.nlm.nih.gov/pubmed/28470944

Roncolato FT, Berton-Rigaud D, O’Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422-1. https://doi.org/10.1016/j.ygyno.2017.10.019

Park, S.B., J.B. Kwok, R. Asher, C.K. Lee, P. Beale, F. Selle, and M. Friedlander, Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol, 2017. 28(11): https://www.ncbi.nlm.nih.gov/pubmed/29117336

M A Bookman, A Okamoto, G Stuart, N Yanaihara, D Aoki, M Bacon, K Fujiwara, A González-Martín, P Harter, J W Kim, J Ledermann, E Pujade-Lauraine, M Quinn, K Ochiai, participants of the 5th Ovarian Cancer Consensus Conference; Harmonising clinical trials within the Gynecologic Cancer InterGroup: consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference, Annals of Oncology, Volume 28, Issue suppl_8, 1 November 2017, Pages viii30–viii35, https://doi.org/10.1093/annonc/mdx449

de Boer SM, Wortman BG, Bosse T, Powell ME, Singh N, Hollema H, Wilson G, Chowdhury MN, Mileshkin L, Pyman J, Katsaros D, Carinelli S, Fyles A, McLachlin CM, Haie-Meder C, Duvillard P, Nout RA, Verhoeven-Adema KW, Putter H, Creutzberg CL, Smit VTHBM; PORTEC study group. Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. Ann Oncol. 2017 Nov 27. https://doi.org/10.1093/annonc/mdx753 PubMed PMID: 29190319.

C.A. Hamilton, A. Miller, Y. Casablanca, N.S. Horowitz, B. Rungruang, T.C. Krivak, S.D. Richard, N. Rodriguez, M.J. Birrer, F.J. Backes, M.A. Geller, M. Quinn, M.J. Goodheart, D.G. Mutch, J.J. Kavanagh, G.L. Maxwell, M.A. Bookman, Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study, Gynecologic Oncology, Available online 28 November 2017, ISSN 0090-8258, https://doi.org/10.1016/j.ygyno.2017.11.018

King MT, Stockler MR, O’Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer. Qual Life Res. 2017 Dec 16. https://doi.org/10.1007/s11136-017-1729-8 [Epub ahead of print] PubMed PMID: 29248998.

Sjoquist, K.M., L.R. Mileshkin, S. Ananda, C.M. Shannon, D. Bowtell, S. Yip, D. Espinoza, J.C. Goh, M.L. Harrison, M. Plebanski, V. Gebski, M.R. Stockler, K. Livingstone, M. Tang, and M. Friedlander, REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC). Journal of Clinical Oncology, 2018. 36(15_suppl): p. 10097-10097DOI: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.10097

Beesley, V.L., D.D. Smith, C.M. Nagle, M. Friedlander, P. Grant, A. DeFazio, P.M. Webb, and O.S. Group, Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Support Care Cancer, 2018DOI: https://link.springer.com/article/10.1007/s00520-018-4284-0

Wilson, M.K., R. Mercieca-Bebber, and M. Friedlander, A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol, 2018. 29(5): https://www.ncbi.nlm.nih.gov/pubmed/30022641